Eisai EMEA
Guy Van Damme has a diverse work experience in the pharmaceutical industry. Guy started their career at UCB Pharma as a University specialist before joining Zeneca Pharmaceuticals as a Hospital Sales and GP representative in Cardiology. Guy then moved on to AstraZeneca as a Junior Product Manager. In 2002, they joined Boehringer Ingelheim Belux where they held various positions including Product Manager, Group Product Manager, Strategic Account Manager, and Marketing Director for Respiratory and Diabetes. In 2015, they joined Zambon as the Specialty Business Unit Director for BeNeLux. Currently, they are working at Eisai EMEA as the Head of Sales and Marketing for Oncology Neurology and also holds the position of Power of Attorney.
From 1983 to 1986, Guy Van Damme attended BME Hoge School Gent, where they earned a bachelor's degree in Marketing.
This person is not in any offices
Eisai EMEA
3 followers
At Eisai, everything we do is dedicated to giving our first thought to patients and their families through our human health care (hhc) philosophy. We are the European hub of Tokyo-based Eisai Co. Ltd., forming part of a multinational team working across a global network of R&D facilities, manufacturing sites and marketing subsidiaries. Our collective passion and dedication to patient care is the driving force behind our efforts to discover and develop innovative medicines in a variety of therapeutic areas in which a high unmet medical need remains, including oncology and neurology. Our mission is clear; we strive to make a significant long-lasting contribution to society in an ethical, compliant and sustainable way by embodying our hhc philosophy in everything we do. For more information about Eisai in the EMEA region please visit www.eisai.eu Our community guidelines can be found here: https://www.eisai.eu/wp-content/uploads/Community-guidelines-v1.0.pdf For more information about how Eisai processes your data, please refer to our privacy policy here: https://www.eisai.eu/privacy-policy/ --- November 2023 | EMEA-NON-23-00180